State

Rhode Island product recalls

73,833 recalls have nationwide distribution and so reach Rhode Island. 3,054 additional recalls listed Rhode Island specifically in their distribution scope.

What the numbers show

Total: 3,054
Critical: 221
Severe: 708
Most recent: 2026-11-04

Of the 3,054 recalls naming Rhode Island we have scored against our rubric, 221 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 708 (23%) are Severe.

Which agencies issued them

These figures cover only the 3,054 recalls whose distribution notice names Rhode Island specifically. The 73,833 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

56201–56225 of 76887

SevereFDA (Drugs)·D-665-2015·2015-04-29
Attix Pharmaceuticals Recalls Etomidate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Etomidate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Etomidate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-586-2015·2015-04-29
Attix Pharmaceuticals Recalls Cimetidine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cimetidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cimetidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-653-2015·2015-04-29
Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-683-2015·2015-04-29
Fluorexon API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluorexon active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Fluorexon active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-953-2015·2015-04-29
Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-930-2015·2015-04-29
Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-906-2015·2015-04-29
Attix Pharmaceuticals Recalls Sulfanilamide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sulfanilamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Sulfanilamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-718-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-556-2015·2015-04-29
Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-606-2015·2015-04-29
Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-764-2015·2015-04-29
Linezolid API Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Linezolid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Linezolid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-883-2015·2015-04-29
Attix Pharmaceuticals Recalls Rocuronium Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Rocuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Rocuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-919-2015·2015-04-29
Attix Pharmaceuticals Recalls Terbinafine Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Terbinafine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Terbinafine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-671-2015·2015-04-29
Famciclovir Recalled Due to Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling famciclovir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Famciclovir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-799-2015·2015-04-29
Attix Pharmaceuticals Recalls Minocycline HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Minocycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Minocycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-957-2015·2015-04-29
Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-758-2015·2015-04-29
Attix Pharmaceuticals Recalls Levofloxacin Hemihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levofloxacin Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Levofloxacin Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-830-2015·2015-04-29
Attix Pharmaceuticals Recalls Pancuronium Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pancuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pancuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-761-2015·2015-04-29
Attix Pharmaceuticals Recalls Levothyroxine Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levothyroxine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levothyroxine Sodium (T4) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-886-2015·2015-04-29
Attix Pharmaceuticals Recalls Roxithromycin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Roxithromycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Roxithromycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-841-2015·2015-04-29
Attix Pharmaceuticals Recalls Phentolamine Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Phentolamine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Phentolamine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-954-2015·2015-04-29
Attix Pharmaceuticals Recalls Vincristine Sulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Vincristine Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Vincristine Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-562-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-727-2015·2015-04-29
Attix Pharmaceuticals Recalls Ibuprofen Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling ibuprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Ibuprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-859-2015·2015-04-29
Attix Pharmaceuticals Recalls Pregabalin Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling pregabalin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Pregabalin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide